SINT SINTX TECHNOLOGIES INC.

SINTX Technologies to Explore Strategic Opportunities

SINTX Technologies to Explore Strategic Opportunities

Salt Lake City, Utah., June 18, 2024 (GLOBE NEWSWIRE) -- SINTX Technologies, Inc. (NASDAQ: SINT) (“SINTX” or the “Company”) today announced that its Board of Directors has initiated a process to explore potential strategic options for the Company.

SINTX has multiple business lines focused on technical materials, with manufacturing and R&D sites located in Salt Lake City and Millersville, MD. In addition to its FDA-approved silicon nitride ceramic spinal fusion devices, the Company has developed ceramic-polymer composites, a novel technology that addresses other medical devices, such as implants for lower extremity fusion. Based on extensive peer-reviewed published data, the key advantages of the Company’s proprietary medical-grade silicon nitride include its proven biocompatibility, inherent resistance to bacteria and viruses, bone cell stimulation, and ease of radiographic imaging. More recently, the Company’s femoral head technology has attracted renewed interest from several global partners. The Company’s silicon nitride is also being utilized in several aerospace engine applications, with two long-term supply agreements in this market.

SINTX also has unique capabilities in 3D printing technologies including Digital Light Projection (DLP) ceramic additive manufacturing, proprietary resin formulations, and extensive pre-print and post-print processing and characterization. The Company has applied Chemical Vapor Infiltration (CVI) and Chemical Vapor Deposition (CVD) manufacturing processes to produce thermal and environmental barrier coatings. These technologies are relevant to many industrial and defense applications, such as hypersonic projectiles, and renewable energy. The company is also one of the few manufacturers of optical ceramic materials for sensor applications. Other proprietary technologies include the manufacture of high performance, lower cost ballistic materials for opaque armor applications at its subsidiary, SINTX Armor. SINTX Armor is expected to begin production of a competitively priced body- and vehicle-protective armor product that has undergone successful testing.

“With technologies targeted at the medical, defense, and renewable energy markets, year-over-year growth in revenues, and other commercial opportunities in the pipeline, SINTX will require additional investment and resources. As such, we want to examine all strategic opportunities targeted at maximizing shareholder value,” said Sonny Bal, Chief Executive Officer and Chairman of SINTX. “We believe that potential partners will find significant value in SINTX’s businesses and capabilities.”

The Company has retained Ascendiant Capital Markets, LLC (), as its exclusive strategic advisor to assist the Board in the review process. Interested parties may reach out to Scott Patten, Managing Director, at for further discussion.

There can be no assurance that the strategic process will result in the Company pursuing any particular transaction or outcome. The SINTX Board has not set a timetable for completion of this process, and it will not disclose further developments until such time that the Company determines that further disclosure is appropriate or necessary.

About SINTX Technologies, Inc.

SINTX Technologies is an advanced ceramics company that develops and commercializes materials, components, and technologies for medical and technical applications. SINTX is a global leader in the research, development, and manufacturing of silicon nitride, and its products have been implanted in humans since 2008. Over the past several years, SINTX has utilized strategic acquisitions and alliances to enter into new markets. The Company has manufacturing and R&D facilities in Utah and Maryland.

For more information on SINTX Technologies or its materials platform, visit .

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 (“PSLRA”) that are subject to a number of risks and uncertainties. Readers are cautioned not to place undue reliance on the forward-looking statements, which speak only as of the date on which they are made and reflect management’s current estimates, projections, expectations and beliefs. There can be no assurance that the company will enter into a strategic transaction or any transaction at all or that if the company does enter into a transaction that shareholder value will be maximized. A discussion of additional risks and uncertainties can be found in SINTX's Risk Factors disclosure in its Annual Report on Form 10-K, filed with the SEC on March 27, 2024, and in SINTX's other filings with the SEC. SINTX disclaims any obligation to update any forward-looking statements. SINTX undertakes no obligation to publicly revise or update the forward-looking statements to reflect events or circumstances that arise after the date of this report.

Business and Media Inquiries for SINTX:

SINTX Technologies

801.839.3502



EN
18/06/2024

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on SINTX TECHNOLOGIES INC.

 PRESS RELEASE

SINTX Technologies Announces Launch of OsseoSculpt™ an Advanced Biolog...

SINTX Technologies Announces Launch of OsseoSculpt™ an Advanced Biologic for Use with SINAPTIC® Foot & Ankle Osteotomy Wedge System Clinical evaluation of the product by design surgeons completed, driving early commercial momentum SALT LAKE CITY, Utah, Nov. 03, 2025 (GLOBE NEWSWIRE) -- SINTX Technologies, Inc. (NASDAQ: SINT) (“SINTX” or the “Company”), a leader in advanced ceramic biomedical applications of silicon nitride (Si₃N₄), today announced the execution of a private label agreement to supply OsseoSculpt™, a next-generation biologic designed to complement the Company’s FDA 510(K) ...

 PRESS RELEASE

SINTX Technologies erhält FDA-Zulassung für SINAPTIC® Fuß- und Sprungg...

SINTX Technologies erhält FDA-Zulassung für SINAPTIC® Fuß- und Sprunggelenk-Implantatsystem Das von der FDA zugelassene und in den USA hergestellte Implantatsystem positioniert SINTX für den Eintritt in den milliardenschweren US-Markt SALT LAKE CITY, Utah, Oct. 20, 2025 (GLOBE NEWSWIRE) -- SINTX Technologies, Inc. (NASDAQ: SINT) („SINTX“ oder das „Unternehmen“), ein führender Anbieter von Hochleistungskeramik mit Spezialisierung auf biomedizinische Anwendungen von Siliziumnitrid (Si₃N₄), gab heute bekannt, dass die US-amerikanische Food and Drug Administration (FDA) die 510(k)-Zulassung ...

 PRESS RELEASE

SINTX Technologies obtiene aprobación de la FDA para el sistema de imp...

SINTX Technologies obtiene aprobación de la FDA para el sistema de implantes SINAPTIC® para pie y tobillo El sistema de implantes, aprobado por la FDA y fabricado en EE. UU., posiciona a SINTX para ingresar al mercado estadounidense de miles de millones de dólares SALT LAKE CITY, Utah, Oct. 20, 2025 (GLOBE NEWSWIRE) -- SINTX Technologies, Inc. (NASDAQ: SINT) (“SINTX” o la “empresa”), líder en cerámicas avanzadas especializado en aplicaciones biomédicas de nitruro de silicio (Si₃N₄), anunció hoy que la Administración de Alimentos y Medicamentos de Estados Unidos (FDA) otorgó la autorizaci...

 PRESS RELEASE

SINTX Technologies 的 SINAPTIC® 足踝植入系统获得 FDA 上市许可

SINTX Technologies 的 SINAPTIC® 足踝植入系统获得 FDA 上市许可 获 FDA 批准且在美国本土制造的植入系统,为 SINTX 进军规模达数十亿美元的美国市场奠定了基础 犹他州盐湖城, Oct. 21, 2025 (GLOBE NEWSWIRE) -- SINTX Technologies, Inc. (NASDAQ: SINT,以下简称 “SINTX” 或“公司”) 是一家先进陶瓷领域的领军企业,主要致力于氮化硅 (Si₃N₄) 在生物医学领域的应用。该公司今日宣布,其 SINAPTIC® Foot & Ankle Osteotomy Wedge System(足踝截骨楔形系统)获得了美国 Food and Drug Administration (FDA,美国食品药品监督管理局) 的 510(k) 上市许可,这将助力 SINTX 正式进入美国足踝重建手术的商业市场。SINTX 计划于 2026 年第一季度在美国商用领域推出该系统,利用其美国本土生产优势推动营收增长与运营效率提升。 SINAPTIC 植入系统将 SINTX 专有的氮化硅生物材料与基于外科医生反馈的植入物设计方案及精心设计的无菌一次性器械套件相结合——该套件经专门研发,旨在提升手术的效率、精准度与可重复性。SINAPTIC 植入系统通过将差异化材料科学与实用外科创新融为一...

 PRESS RELEASE

SINTX Technologies 獲 FDA 批准 SINAPTIC® 足踝植入系統

SINTX Technologies 獲 FDA 批准 SINAPTIC® 足踝植入系統 獲 FDA 批准並在美國製造的植入系統推動 SINTX 進軍價值數十億美元的美國市場 猶他州鹽湖城, Oct. 21, 2025 (GLOBE NEWSWIRE) -- 專注於氮化矽 (Si₃N₄) 生物醫學應用的先進陶瓷創新公司 SINTX Technologies, Inc. (NASDAQ: SINT) (「SINTX」或「公司」) 今天宣佈 SINAPTIC® Foot & Ankle Osteotomy Wedge System(足踝截骨楔形系統)獲得 U.S. Food and Drug Administration (FDA) 510(k) 許可,使 SINTX 得以商業進軍美國足踝重建手術市場。SINTX 計劃於 2026 年第一季度在美國作商業化推出,運用其美國本土生產優勢推動收益增長及營運效率。 SINAPTIC 植入系統結合 SINTX 專利的氮化矽生物材料、經外科醫生實證的植入設計,以及計劃中無菌單次使用器械套件,旨在提升手術效率、精準度及可重複性。透過結合別樹一幟的材料科學與實用手術創新,SINAPTIC 植入系統體現 SINTX 將其獨特生物材料平台轉化為可擴展、高價值醫療方案的策略,以應對未滿足的臨床需求,並推動長期增長。 商務總監 Lisa Ma...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch